

Remarks


As a further response to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures, having a mailing date of June 18, 2002, Applicants respectfully submit the aforementioned amendments to the specification. The amendments instruct the insertion of the revised "Sequence Listing". In addition, the amendments also instruct the insertion of corresponding sequence identification numbers into the specification.

The Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures, having a mailing date of June 18, 2002, required Applicants to revise the "Sequence Listing" to include the sequences found in Figure 1. Therefore, Applicants revised Figures 1A and 1B to insert the corresponding sequence identification numbers. Applicants respectfully request that Figures 1A and 1B be deleted and replaced by the attached revised Figures 1A and 1B.

Applicants believe they have now fully complied with the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures, having a mailing date of June 18, 2002, a copy of which is enclosed herewith as required.

Early and favorable consideration is requested.

Respectfully submitted,


Stephen G. Ryan, 39,015
Attorney for Applicants

Amersham Biosciences Corp
800 Centennial Avenue
P. O. Box 1327
Piscataway, NJ 08855-1327

Tel: (732) 457-8071
Fax: (732) 457-8463

I hereby certify that this correspondence is being deposited with
the United States Postal Service as first class mail in an envelope
addressed to: Commissioner of Patents and Trademarks, Washington,
D.C. 20231, on 10 July 02.

Melissa Leck
Signature Melissa Leck
Date July 10, 2002

Specification (marked up version showing amendments)

The paragraph at page 5, lines 10-21:

The above and other objects and advantages of the present invention will be apparent upon consideration of the following detailed description taken in conjunction with the accompanying drawings, in which like characters refer to like parts throughout, and in which:

FIG. 1 (a) schematizes the protein domain structure of NHELP1 and FIG. 1 (b) shows the alignment of the Na₂H₂Exchanger domain with that of other proteins (SEQ ID No. 3057); (SEQ ID No. 3058); (SEQ ID No. 3059); (SEQ ID No. 3060); and (SEQ ID No. 3061);

FIG. 2 is a map showing the genomic structure of NHELP1 encoded at chromosome 3q23; and

FIG. 3 presents the nucleotide and predicted amino acid sequences of NHELP1 (SEQ ID No. 1) and (SEQ ID No. 3).

Specification (clean version encompassing amendments)

The paragraph at page 5, lines 10-21:

a' The above and other objects and advantages of the present invention will be apparent upon consideration of the following detailed description taken in conjunction with the accompanying drawings, in which like characters refer to like parts throughout, and in which:

FIG. 1 (a) schematizes the protein domain structure of NHELP1 and FIG. 1 (b) shows the alignment of the Na₂H₂Exchanger domain with that of other proteins (SEQ ID No. 3057); (SEQ ID No. 3058); (SEQ ID No. 3059); (SEQ ID No. 3060); and (SEQ ID No. 3061);

FIG. 2 is a map showing the genomic structure of NHELP1 encoded at chromosome 3q23; and

FIG. 3 presents the nucleotide and predicted amino acid sequences of NHELP1 (SEQ ID No. 1) and (SEQ ID No. 3).
